You are here: Industry Insights > Review

News List

Monthly News Review of PharmaSources (February) - Business Caicai/PharmaSources
March 14, 2023
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
A Review of Chinese-produced Class 1 New Drugs from 2018 to 2020 PharmaSources/Caicai
January 28, 2021
From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic.
China’s regulator agrees to review BeiGene’s tislelizumab pharmaceutical-technology
June 05, 2019
The National Medical Products Administration (NMPA) in China has agreed to review BeiGene’s supplemental new drug application (sNDA) of tislelizumab in urothelial carcinoma (UC).
FDA decisions could ‘slow to crawl’ because of government shutdown pharmaphorum
January 21, 2019
Experts have said the ongoing government shutdown may already have delayed approval and launch of new drugs, as the FDA’s spare cash reserves dwindle with every day that the impasse continues.
Launch woes, crossed fingers, a 'bulletproof' FDA review and more fiercepharma
January 10, 2019
The J.P. Morgan Healthcare Conference opened Tuesday with some anticipation for GlaxoSmithKline CEO Emma Walmsley's talk, what with the pharma giant's recent deal to buy cancer drugmaker Tesaro.
Health secretary orders review overprescribing pharmatimes
December 11, 2018
Health secretary Matt Hancock has ordered a review of patients who take multiple medicines, to ensure they are receiving the most appropriate treatment for their needs, and avoid needless overprescribing.
Review signals step towards legalisation of medicinal cannabis in UK pharmafile
July 06, 2018
England’s Chief Medical Officer Dame Sally Davies has concluded that there is “conclusive evidence” that cannabis is medically beneficial for some patients in specific conditions.
US priority review for AZ’ Tagrisso pharmatimes
December 19, 2017
US regulators are undertaking a speedy review of AstraZeneca's application to market Tagrisso as first-line treatment for lung cancer.